Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recaticimab and Adebrelimab with Chemotherapy in Advanced Biliary Tract Carcinoma
NCT07062328Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
01
Overview
A Phase 2 trial of recaticimab, adebrelimab in biliary tract carcinoma (BTC), sponsored by Sun Yat-sen University. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
recaticimabadebrelimab
03
Conditions
biliary tract carcinoma (BTC)
Beyond the preview
Go deeper on NCT07062328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07062328.